AstraZeneca PLC AZN
Set alert
At close
Pre-market · Nov 2, 8:48 AM ET
- YTD
- +1.52%
- 1 year
- +13.34%
- Open
- 183.59
- Prev close
- 174.40
- Mkt cap
- 289.48B
- Vol
- 5.38M
- Avg vol
- 3.47M
- EPS
- 7.07
- P/E
- 26.40
- Div yield
- 1.24%
More statistics
- Low
- 183.10
- High
- 188.39
- Forward P/E
- 16.41
- Beta
- 0.21
- Short ratio
- 1.14
- Inst. own
- 76.35%
- Dividend
- 3.20
- Ex-div date
- Aug 6, 2026
- Earnings
- Feb 9, 2027
- 50-d avg
- 164.04
- 200-d avg
- 180.19
- 1y target
- 206.66
5D chart
Events in this range
- Oct 30, 2026Earnings: 2.79; estimate 2.6; surprise 7.31%
Signals (127)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:00 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 2 days ago |
| RSI: Overbought | Oct 30, 12:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:35 PM | 2 days ago |
| RSI: Overbought | Oct 30, 12:35 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 10:50 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:30 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:15 AM | 2 days ago |
| RSI: Overbought | Oct 30, 9:30 AM | 3 days ago |
| RSI: Overbought | Oct 29, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:50 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:40 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:15 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:45 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:10 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| RSI: Overbought | Oct 28, 10:50 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 5 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:50 PM | 5 days ago |
| RSI: Oversold | Oct 27, 1:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:45 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:20 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:35 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:25 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:20 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:15 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:10 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 6 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 6 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 6 days ago |
| MACD: Sell Signal | Oct 27, 9:35 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 6 days ago |
| RSI: Overbought | Oct 26, 3:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:35 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:15 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:35 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:35 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:20 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:20 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:40 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:35 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:30 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:40 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:35 AM | 6 days ago |
News
23 hours ago fool.com
AstraZeneca: 3 Key Takeaways for Long-Term Investors
Total revenue grew 7% across the first nine months of 2026. AstraZeneca launched a $2 billion restructuring initiative through 2029.
2 days ago defenseworld.net
AstraZeneca (NYSE:AZN) Share Price Crosses Above 200 Day Moving Average – Time to Sell?
AstraZeneca Plc (NYSE: AZN - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $180.21 and traded as high as…
2 days ago defenseworld.net
AstraZeneca Plc $AZN Shares Acquired by Brian Low Financial Group LLC
Brian Low Financial Group LLC increased its position in shares of AstraZeneca Plc (NYSE: AZN) by 32.6% during the third quarter, according to the company in its most recent disclosure with the…
2 days ago defenseworld.net
AstraZeneca (LON:AZN) Share Price Crosses Above Two Hundred Day Moving Average – Time to Sell?
AstraZeneca PLC (LON: AZN - Get Free Report) passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of £134.30 and traded as high as £140.02.…
2 days ago seekingalpha.com
AstraZeneca PLC (AZN) Q3 2026 Earnings Call Transcript
AstraZeneca PLC (AZN) Q3 2026 Earnings Call Transcript
2 days ago marketbeat.com
AstraZeneca Q3 Earnings Call Highlights
AstraZeneca NYSE: AZN reported continued revenue and earnings growth for the first nine months of 2026, supported by double-digit expansion in oncology, rare disease and respiratory and immunology,…
2 days ago benzinga.com
AstraZeneca Q3 2026 Earnings Call Transcript
AstraZeneca (NASDAQ:AZN) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
2 days ago zacks.com
AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth
AstraZeneca beats Q3 earnings and revenue estimates as oncology sales surge 17%, offsetting generic pressure on mature drugs.
2 days ago benzinga.com
AstraZeneca Stock Rallies on Q3 Earnings Beat, Double-Digit Oncology Growth
AstraZeneca Plc (NYSE:AZN) on Friday posted better-than-expected third-quarter 2026 results. The European drug giant reported core earnings of $2.79 per share, beating the consensus of $2.59.
2 days ago benzinga.com
AstraZeneca Stock Rallies on Q3 Earnings Beat, Double-Digit Oncology Growth
AstraZeneca beats Q3 2026 targets as oncology offsets Farxiga losses, backed by a $2 billion pipeline restructuring push.
2 days ago zacks.com
Astrazeneca (AZN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
2 days ago youtube.com
AstraZeneca CFO on AI, Earnings, Restructuring Plan
AstraZeneca Chief Financial Officer Aradhana Sarin says the drug company uses AI in almost every aspect of the work they do. She talks beating on earnings, their drug pipeline and how the company…
2 days ago benzinga.com
AutoNation, Regeneron Pharmaceuticals, AstraZeneca And Other Big Stocks Moving Higher On Friday
U.S. stocks fell Friday, but AutoNation jumped 8% after beating Q3 estimates; OneSpan, Grid Dynamics and others posted double-digit gains.
3 days ago benzinga.com
Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Trade Mixed as AMZN, INTC Slide After Q3 Earnings—DELL, LLY, AZN in Focus (UPDATED)
U.S. stock were mixed on Friday, as the Dow Jones, S&P 500, and Nasdaq 100 index futures moved in different direction.
3 days ago barrons.com
AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling Stock
AstraZeneca aims to free up funds to reinvest into its pipeline and meet its goal of $80 billion in annual revenue by 2030.
3 days ago businesswire.com
AstraZeneca results: 9M and Q3 2026
CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary 9M 2026 % Change Q3 2026 % Change $m Actual CER1 $m Actual CER - Product Sales 43,962 7 5 15,066 5 5 - Alliance Revenue 2,806…
3 days ago reuters.com
FTSE 100 set for monthly gains; AstraZeneca up after results
London's FTSE 100 looked on track to log its first monthly gain in three months, edging up on Friday as AstraZeneca rose, with investors welcoming a budget that was softer than expected on taxes.
-
3 days ago benzinga.com
AstraZeneca Shares Rise After Q3 Earnings Beat, Reaffirmed 2026 Outlook
AstraZeneca Plc (NASDAQ:AZN) shares are trading higher Friday after the drugmaker reported third-quarter results that topped analyst estimates and reaffirmed its full-year guidance.What To Know:…
3 days ago wsj.com
AstraZeneca Posts Revenue, Profit Growth on Strong Cancer-Drug Sales
The U.K. drugmaker reported net profit of $3.12 billion for the third quarter, up from $2.535 billion for the same period last year.
3 days ago benzinga.com
Stock Market: Will S&P 500 Open Up or Down Today?
Will S&P 500 open higher? Polymarket odds plunge to 14% as Wall Street reacts to Alphabet's 10% drop, rising oil, and a broad tech selloff.
3 days ago benzinga.com
ExxonMobil, AbbVie On Deck Friday As Energy, Drug Growth Face Test
ExxonMobil headlines Friday’s reports, with investors watching whether strong energy production can sustain a sharp earnings recovery. AbbVie, Chevron, AstraZeneca, BP, Sanofi, General Dynamics,…
5 days ago businesswire.com
AstraZeneca and Mark-Paul Gosselaar Launch Meet Your Mark to Raise Awareness of Cancer Biomarker Testing
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the launch of Meet Your Mark, a new public health campaign featuring actor Mark-Paul Gosselaar. The campaign encourages people to ask…
5 days ago seekingalpha.com
Allspring Emerging Growth Fund: Q3 2026 Top Contributors And Detractors
After delivering results well above expectations, TWST management significantly raised its outlook and projected triple-digit growth in orders. During the quarter, LIFE shares performed well…
5 days ago businesswire.com
Breast Cancer Canada and AstraZeneca Canada Advance Next-Generation Survivorship Research
TORONTO--(BUSINESS WIRE)--Breast Cancer Canada and AstraZeneca Canada are investing $200,000 in matched research funding to address critical gaps in breast cancer survivorship and improve care for…
6 days ago seekingalpha.com
Parnassus Value Equity Fund Q3 2026 Portfolio Review
Parnassus Value Equity Fund (Investor Shares) returned -1.38% (net of fees) for the quarter, underperforming the Russell 1000 Value Index's 2.61%. Top contributors include Thermo Fisher, CME Group,…
-
6 days ago benzinga.com
Daiichi Sankyo Gets $75M Milestone From AstraZeneca After EU Approves Enhertu For Adjuvant HER2 Positive Early Breast Cancer; DESTINY-Breast05 Showed 53% Lower Recurrence Or Death Risk Versus T-DM1
Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1First EU…
6 days ago marketbeat.com
AstraZeneca Highlights Breakthrough Cancer Data at ESMO 2026 Investor Update
Astrazeneca NYSE: AZN highlighted new clinical data across bladder, lung and gastric cancers at its ESMO 2026 investor event, including four presidential presentations that executives said support…
6 days ago globenewswire.com
Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
DENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- (247marketnews. com) - Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), AstraZeneca (NYSE: AZN), and Roche (OTCQX: RHHBY) are among the biopharma companies…
1 week ago benzinga.com
Amgen, AstraZeneca Drug Combo Shows Promising Survival Results in Tough-To-Treat Lung Cancer
Amgen's Imdelltra with Imfinzi cut small-cell lung cancer death risk by 58% in Phase 3, extending median survival to 21.1 months. Read more.
1 week ago 247wallst.com
Is AstraZeneca's Pipeline Fuel Enough to Spark a Post-Earnings Breakout on Oct. 30?
AstraZeneca (NYSE:AZN | AZN Price Prediction) reports third-quarter results on Friday, October 30. Farxiga generics are cutting into sales, and a major cardiology trial has failed.
1 week ago fool.com
Breakfast News: Science Strikes Back at Cancer
Cancer trial data shines at ESMO 2026, earnings flood after tough market week, and more…
1 week ago gurufocus.com
AZN DCF Analysis: Intrinsic Value $90 vs Price $171
On October 26, 2026, we delve into the DCF analysis for AstraZeneca PLC (AZN), a company that has seen a mixed performance in the market. Over the past year, AZ
1 week ago seekingalpha.com
Baron Health Care Fund: Q3 2026 New Positions And Exits
During the quarter, we added 4 new positions and exited 14, bringing the number of positions in the Fund to 33. We initiated a position in Biogen Inc., a company that we believe is in the early…
1 week ago seekingalpha.com
Baron Health Care Fund Q3 2026 Top Contributors And Detractors
TMO's organic growth of 5% exceeded consensus by 200 basis points, and management raised full-year organic growth guidance/. MTD's local-currency sales grew 6%, exceeding prior guidance of 3%. TEVA…
-
1 week ago benzinga.com
AstraZeneca Announced Saturday,Perioperative IMFINZI Plus Neoadjuvant Enfortumab Vedotin Cuts Recurrence Risk 49%, Death Risk 42% Versus Standard Of Care In Muscle-Invasive Bladder Cancer Patients Ineligible For Or Refusing Cisplatin, VOLGA Phase III
More than three quarters of patients were still alive two years after treatment with perioperative IMFINZI plus three cycles of EV given before surgeryData demonstrated statistically significant and…
-
1 week ago benzinga.com
AstraZeneca Announced Saturday, IMFINZI Plus Tarlatamab-dlle Cuts Death Risk 58% Versus IMFINZI Alone In First-Line Extensive-Stage Small Cell Lung Cancer, Median OS 21.1 Versus 12.7 Months, In DeLLphi-305 Phase III
Novel combination demonstrated a median overall survival of nearly two years, the longest benefit ever reported in extensive stage disease in a Phase III trialResults reinforce IMFINZI as the…
1 week ago benzinga.com
FDA Conditionally Approves AstraZeneca's Rare Kidney Disease Drug
FDA grants accelerated approval to AstraZeneca's Ultomiris for adult IgAN to lower proteinuria, pending data on long-term kidney benefit.
-
1 week ago benzinga.com
AstraZeneca Launches ZEGFROVY In The U.S., Expanding Targeted Treatment Options For EGFR Exon 20 Insertion-Mutated Lung Cancer
Only approved oral, single agent, targeted therapy for these patients following platinum-based chemotherapyLaunch expands AstraZeneca’s commitment to addressing substantial unmet need across the…
-
1 week ago benzinga.com
Reported Earlier, AstraZeneca’s Alexion Wins US Accelerated Approval For Ultomiris As First C5 Inhibitor To Reduce Proteinuria In IgA Nephropathy Adults; Phase III I CAN Shows 43.4% Reduction Versus Placebo At 34 Weeks
Based on I CAN Phase III trial results from prespecified interim analysis in which Ultomiris demonstrated 43.4% reduction in proteinuria vs placebo at 34 weeks Late-breaking results from I CAN Phase…
1 week ago benzinga.com
AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study
AstraZeneca and Amgen report positive Phase 3 Tezspire data, showing sustained remission in eosinophilic esophagitis patients over 52 weeks.
1 week ago benzinga.com
'A Surprisingly Large Amount Of Your Investment Is Divided Across Just 7 Companies' — Former Investment Banker Says She's Changing How She Invests
The S&P 500 has long been a favorite among investors looking to build wealth, with historical annual returns averaging around 10%. But former investment banker Nischa Shah says she’s changing how she…
-
1 week ago benzinga.com
Amgen, AstraZeneca Announces Data From Phase 3 CROSSING Study Demonstrated TEZSPIRE Showed Histologic Remission For 64.8% For 210 Mg Dose At Week 24; TEZSPIRE Also Reduced Frequency, Severity Of Dysphagia Symptoms 18.8 Points
Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the positive Phase 3 CROSSING trial that showed TEZSPIRE® (tezepelumab-ekko) demonstrated statistically significant and…
-
1 week ago benzinga.com
AstraZeneca And Amgen's TEZSPIRE Met Co-Primary Endpoints In Phase III EoE Trial
First and only biologic therapy to achieve statistically significant and clinically meaningful histologic remission and symptom improvements at week 24 that were sustained through week 52 vs.…
1 week ago benzinga.com
Oracle Joins Forces With AstraZeneca to Put AI to Work in Drug Research
Oracle and AstraZeneca partner to advance AI-driven clinical trials, speed up recruitment, and connect research to patient care.
-
1 week ago benzinga.com
Oracle Announces Non-Binding Agreement With AstraZeneca To Explore AI And Real-World Data For Clinical Trial Patient Identification, Evidence Generation And Care Insights
Collaboration to connect AstraZeneca's scientific and therapeutic expertise with Oracle's real-world data, cloud, AI, and clinical capabilities to accelerate clinical research and bring…
2 weeks ago benzinga.com
Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push
Shah Capital sells 2.87M Novavax (NVAX) shares for $32.6M, ends activist campaign, and shifts to a family office structure.
-
2 weeks ago benzinga.com
AstraZeneca To Present 100+ Cancer Research Abstracts, Including Five Phase III Trials, At ESMO 2026
CLARITY-Gastric01 data will demonstrate potential of Sone-Ve to establish new treatment for broad population of CLDN18.2-positive gastric cancer patientsSAFFRON results will highlight clinical…
2 weeks ago benzinga.com
AstraZeneca Turns to AI to Crack Tough Heart and Liver Diseases in Billion-Dollar Deal
AstraZeneca pairs with Insitro on a $1.5B AI collaboration to advance drug targets for MASH and heart conditions.
3 weeks ago benzinga.com
AstraZeneca Says Rare Disease Drug Shows Improvements in Inherited Bone Disorder Despite Missing Key Trial Goal
AstraZeneca releases Phase 3 HICKORY trial data for efzimfotase alfa in hypophosphatasia (HPP), showing key secondary improvements.
-
3 weeks ago benzinga.com
Guardant Health Receives European Approval Of Guardant360 CDx As Companion Diagnostic For AstraZeneca’s ETCAMAH
Guardant360 CDx can now help identify cancer mutations earlier and drive improved patient outcomes in major global geographiesThis latest approval marks Guardant’s 31st CDx approval